Short answer
IDEAYA Biosciences, Inc. (IDYA) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 8.01 (Other Events). IDEAYA and Roche will test IDE892 with RG6505 in MTAP-deleted PDAC, expanding IDE892’s clinical development into a high-need setting.
IDEAYA Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- IDEAYA and Roche will test IDE892 with RG6505 in MTAP-deleted PDAC, expanding IDE892’s clinical development into a high-need setting
- IDEAYA sponsors the trial while Roche supplies RG6505, reducing IDEAYA’s clinical-supply burden but creating execution dependence on Roche
- MTAP deletions occur in up to 40% of PDAC, with almost all affected tumors carrying RAS mutations
- Each company retains commercial rights to its compounds, preserving potential standalone and combination economics
- Collaboration may advance to an IDE892, RG6505, and IDE397 triplet, subject to joint approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IDEAYA Biosciences, Inc. 8-K filings
Get the next IDYA 8-K as it lands
Follow IDYA for push alerts, or ask the research agent what this filing means.